Blood, Год журнала: 2020, Номер 136(15), С. 1722 - 1734
Опубликована: Июль 2, 2020
Язык: Английский
Blood, Год журнала: 2020, Номер 136(15), С. 1722 - 1734
Опубликована: Июль 2, 2020
Язык: Английский
Cell, Год журнала: 2020, Номер 181(1), С. 46 - 62
Опубликована: Апрель 1, 2020
Язык: Английский
Процитировано
367Nature Reviews Drug Discovery, Год журнала: 2020, Номер 19(7), С. 463 - 479
Опубликована: Апрель 6, 2020
Язык: Английский
Процитировано
235Nature reviews. Immunology, Год журнала: 2018, Номер 18(10), С. 605 - 616
Опубликована: Июль 25, 2018
Язык: Английский
Процитировано
205Nature Biotechnology, Год журнала: 2019, Номер 37(12), С. 1425 - 1434
Опубликована: Июнь 3, 2019
Язык: Английский
Процитировано
177Signal Transduction and Targeted Therapy, Год журнала: 2021, Номер 6(1)
Опубликована: Май 14, 2021
Abstract Rapid development of vaccines and therapeutics is necessary to tackle the emergence new pathogens infectious diseases. To speed up drug discovery process, conventional pipeline can be retooled by introducing advanced in vitro models as alternatives disease employing technology for production medicine cell/drug delivery systems. In this regard, layer-by-layer construction with a 3D bioprinting system or other technologies provides beneficial method developing highly biomimetic reliable research. addition, high flexibility versatility offer advantages effective vaccines, therapeutics, relevant Herein, we discuss potential control We also suggest that research could significant platform rapid automated tissue/organ medicines near future.
Язык: Английский
Процитировано
113Frontiers in Bioengineering and Biotechnology, Год журнала: 2022, Номер 10
Опубликована: Июнь 22, 2022
Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the body from pathogenic invaders can be used as tools to enhance body’s defense mechanisms against cancer genetically engineering these immune cells. Several strategies have been identified for treatment evaluated their efficacy other diseases such autoimmune infectious diseases. One of most advanced technologies is chimeric antigen receptor (CAR) T-cell therapy, pioneering therapy oncology field. Successful clinical trials resulted approval six CAR-T cell products Food Drug Administration hematological malignancies. However, there various obstacles that limit use CAR first line mechanism cancer. Various innovative therapeutic designs preclinical trial settings demonstrated much potential development. Such testing suitability CARs solid tumors HIV are showing promising results. In addition, new solutions proposed overcome limitations this therapy. This review provides an overview current knowledge regarding novel technology, including structure, different applications, limitations, solutions.
Язык: Английский
Процитировано
74Viruses, Год журнала: 2024, Номер 16(2), С. 219 - 219
Опубликована: Янв. 31, 2024
Chronic Human Immunodeficiency Virus (HIV) infection remains a significant challenge to global public health. Despite advances in antiretroviral therapy (ART), which has transformed HIV from fatal disease into manageable chronic condition, definitive cure elusive. One of the key features is immune activation and inflammation, are strongly associated with, predictive of, progression, even patients successfully treated with suppressive ART. inflammation characterized by persistent cell metabolic dysregulation, cellular exhaustion dysfunction. This review aims summarize current knowledge interplay between metabolism, T dysfunction infection, also discusses use humanized mice models study pathogenesis develop novel therapeutic strategies.
Язык: Английский
Процитировано
29Science Translational Medicine, Год журнала: 2019, Номер 11(504)
Опубликована: Авг. 7, 2019
Multispecific duoCAR-T cells potently suppress HIV infection in a humanized mouse model.
Язык: Английский
Процитировано
128Nature, Год журнала: 2019, Номер 576(7787), С. 397 - 405
Опубликована: Дек. 18, 2019
Язык: Английский
Процитировано
124Frontiers in Microbiology, Год журнала: 2018, Номер 9
Опубликована: Дек. 21, 2018
The advances in cancer biology and pathogenesis during the past two decades, have resulted immunotherapeutic strategies that revolutionized treatment of malignancies, from relatively non-selective toxic agents to specific, mechanism-based therapies. Despite extensive global efforts, infectious diseases remain a leading cause morbidity mortality worldwide, necessitating novel, innovative therapeutics address current challenges increasing antimicrobial resistance. Similar pathogenesis, pathogens successfully fashion hospitable environment within host modulate metabolic functions support their nutritional requirements, while suppressing defenses by altering regulatory mechanisms. These parallels, made targeted therapy cancer, may inform rational development therapeutic interventions for diseases. Although "immunotherapy" is habitually associated with this review accentuates evolving role key immune are approved, as well those development, various cancers general features adoptive therapies, enhance T cell effector function, ligand-based neutralize or eliminate diseased cells, discussed context specific that, date, lack appropriate remedial treatment; HIV, TB drug-resistant bacterial fungal infections. remarkable diversity versatility distinguishes immunotherapy emphasized, consequently establishing approach armory curative therapeutics, applicable across disease spectrum.
Язык: Английский
Процитировано
104